Economic evaluation of pneumococcal conjugate vaccination in The Gambia

BACKGROUND: Gambia is the second GAVI support-eligible country to introduce the 7-valent pneumococcal conjugate vaccine (PCV7), but a country-specific cost-effectiveness analysis of the vaccine is not available. Our objective was to assess the potential impact of PCVs of different valences in The Ga...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Sun-Young, Lee, Gene, Goldie, Sue J
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2944347/
https://www.ncbi.nlm.nih.gov/pubmed/20815900
http://dx.doi.org/10.1186/1471-2334-10-260

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2944347/
https://www.ncbi.nlm.nih.gov/pubmed/20815900
http://dx.doi.org/10.1186/1471-2334-10-260

Ejemplares similares